Özkurt Enver, Ordu Çetin, Koç Ertan, Gokmen Erhan, Ozdogan Mustafa, Guler Nilufer, Uras Cihan, Öz Bahadır, Demircan Orhan, Isikdogan Abdurrahman, Saip Pinar, Ozmen Vahit
Department of General Surgery, Faculty of Medicine, Demiroğlu Bilim University, Istanbul, Türkiye.
Department of Medical Oncology, Faculty of Medicine, Demiroğlu Bilim University, Istanbul, Türkiye.
World J Surg. 2025 Sep;49(9):2303-2313. doi: 10.1002/wjs.70025. Epub 2025 Aug 1.
Seventy percent of early-stage breast cancers are hormone receptor positive. In this prospectively designed study, we aim to update the long-term survival outcomes of chemotherapy decision-making according to Oncotype DX Recurrence Score (ODX-RS) and its relation with different cut-offs.
Ten academic centers in Türkiye that routinely discuss all new cases at multidisciplinary tumor board participated. Consecutive patients who are pT1-3, pN0-N1mic, M0 were identified. Adjuvant treatment decisions were discussed at tumor board before and after ODX-RS results.
Of the 165 patients (26-76, median 48 years) with a median follow-up of 108 months, ODX-RS ≤ 25 had significantly better overall survival (OS) than those with ODX-RS ≥ 26 (p = 0.022). When evaluated by age, OS and disease-free survival (DFS) was significantly better with ODX-RS ≤ 15 in patients aged ≤ 50 years and with ODX-RS ≤ 25 in patients aged > 50 years (p = 0.034 and p = 0.024). ODX-RS ≤ 20 in patients aged ≤ 50 years and ODX-RS ≤ 25 in patients aged > 50 years had significantly better OS (p = 0.002). There was no difference in OS between those who received chemotherapy before ODX-RS and those who did not (p = 0.119). Conversely in the post-ODX-RS, ODX-RS predicted survival better and OS was lower in patients who received chemotherapy compared to those who did not (p = 0.020) meaning that ODX-RS can predict OS. The ODX-RS test significantly reduced overall chemotherapy-related costs, yielding a favorable ICER of $3787.5 per QALY gained, thus demonstrating its cost-effectiveness.
The ODX-RS significantly influences treatment decisions resulting comparable survivals for patients who received chemotherapy and who did not. Different cut-offs have variable significant prognostic effect on survival prediction models.
70%的早期乳腺癌为激素受体阳性。在这项前瞻性设计的研究中,我们旨在更新根据Oncotype DX复发评分(ODX-RS)进行化疗决策的长期生存结果及其与不同临界值的关系。
土耳其的10个学术中心参与了此项研究,这些中心会在多学科肿瘤委员会中定期讨论所有新病例。纳入了pT1-3、pN0-N1mic、M0的连续患者。在获得ODX-RS结果前后,在肿瘤委员会中讨论辅助治疗决策。
165例患者(年龄26 - 76岁,中位年龄48岁)的中位随访时间为108个月,ODX-RS≤25的患者总生存期(OS)显著优于ODX-RS≥26的患者(p = 0.022)。按年龄评估,年龄≤50岁的患者中ODX-RS≤15时OS和无病生存期(DFS)显著更好,年龄>50岁的患者中ODX-RS≤25时OS和DFS显著更好(p = 0.034和p = 0.024)。年龄≤50岁的患者中ODX-RS≤20以及年龄>50岁的患者中ODX-RS≤25时OS显著更好(p = 0.002)。在获得ODX-RS结果之前接受化疗和未接受化疗的患者之间OS无差异(p = 0.119)。相反,在获得ODX-RS结果之后,ODX-RS对生存的预测更好,接受化疗的患者的OS低于未接受化疗的患者(p = 0.020),这意味着ODX-RS可以预测OS。ODX-RS检测显著降低了总体化疗相关成本,每获得一个质量调整生命年(QALY)的增量成本效果比(ICER)为3787.5美元,从而证明了其成本效益。
ODX-RS显著影响治疗决策,接受化疗和未接受化疗的患者生存率相当。不同的临界值对生存预测模型有不同程度的显著预后影响。